8-K: Protagonist Therapeutics Reports Strong 2024 Financial Results Driven by Collaboration Revenue and Pipeline Progress

Protagonist Therapeutics announces positive financial results for Q4 and full-year 2024, highlighted by a $165.0 million milestone payment and advancements in its clinical programs.

Summary

• Protagonist Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company earned a $165.0 million milestone in Q4 2024 from the icotrokinra (formerly JNJ-2113) collaboration, which was received in January 2025.
• PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide, was nominated as a development candidate in Q4 2024.
• Topline results for the rusfertide Phase 3 VERIFY clinical trial in polycythemia vera and the icotrokinra Phase 2b ANTHEM clinical trial in ulcerative colitis are expected in March 2025.
• As of December 31, 2024, the company had $559.2 million in cash, cash equivalents, and marketable securities, which, combined with the milestone payment, is expected to provide a cash runway through at least the end of 2028.
• License and collaboration revenue increased by $374.4 million, from $60.0 million in 2023 to $434.4 million in 2024, primarily due to the Takeda agreement and increased revenue from the JNJ agreement.
• Net income for the full year 2024 was $275.2 million, compared to a net loss of $(79.0) million in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, promising clinical trial progress, and strategic collaborations. The company's strong cash position and pipeline advancements contribute to a favorable sentiment.

Positives

• The company has a strong cash position of $559.2 million, providing a runway through at least the end of 2028.
• The company achieved positive topline results for the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies for Icotrokinra.
• The company has multiple late-stage transformational events expected in the first quarter of this year.
• The company has a worldwide license and collaboration agreement for rusfertide with Takeda, receiving an upfront cash payment of $300.0 million.
• The company reported net income of $275.2 million for the full year 2024, a significant turnaround from the previous year's net loss.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated.
• These risks include the ability to develop and commercialize product candidates, earn milestone payments, obtain regulatory approval, and compete successfully.

Future Outlook

The company anticipates multiple late-stage transformational events in the first quarter of this year, including topline results from the VERIFY Phase 3 study of rusfertide and the ANTHEM Phase 2b ulcerative colitis study of icotrokinra. The company also expects to nominate an oral development candidate in the hepcidin mechanism-based hematology program in Q4 2025, and an oral peptide-based development candidate in the metabolic/obesity program in Q2 2025.

Management Comments

• Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra, said Dinesh V. Patel, Ph.D., the Company's President and CEO.
• We are fortunate to be in a strong cash position, enabling the flexibility to progress these early-stage peptide drug candidates independently into pre-clinical and clinical proof-of-concept studies over the coming years.

Industry Context

Protagonist Therapeutics' focus on oral peptide therapeutics, particularly in areas like IL-23 and IL-17 antagonism, aligns with the industry's growing interest in oral biologics and targeted therapies. The collaborations with major pharmaceutical companies like Takeda and JNJ highlight the value of Protagonist's platform and pipeline.

Comparison to Industry Standards

• Protagonist's icotrokinra, an oral IL-23 receptor antagonist, competes with injectable biologics like Skyrizi (risankizumab) and Tremfya (guselkumab) from AbbVie and Johnson & Johnson, respectively.
• The Phase 3 ICONIC-LEAD study showed that 64.7% of patients treated with icotrokinra achieved IGA scores of 0/1 at week 16, which is comparable to the efficacy seen with injectable IL-23 inhibitors.
• Protagonist's rusfertide, a hepcidin mimetic, is being developed for polycythemia vera, a rare blood disorder, and its co-development with Takeda positions it to compete with existing treatments like phlebotomy and hydroxyurea.
• The company's PN-881, an oral IL-17 antagonist, aims to compete with injectable IL-17 inhibitors like Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and pipeline progress.
• Employees may be motivated by the company's success and future prospects.
• Patients may benefit from the development of new oral peptide therapeutics.
• Collaborators like Takeda and JNJ will continue to work with Protagonist on drug development and commercialization.

Next Steps

• The company expects topline results for the Phase 3 VERIFY study in PV and the Phase 2b ANTHEM study in ulcerative colitis in March 2025.
• The company expects topline results for the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 superiority studies in Q2 2025.
• The company expects to nominate an oral peptide-based development candidate in the obesity program in Q2 2025.
• The company expects to nominate an oral development candidate in the hepcidin mechanism-based hematology program in Q4 2025.
• Further details of the Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies are expected to be presented at major medical conferences this year.

Key Dates

Keywords

Protagonist Therapeutics, financial results, icotrokinra, rusfertide, clinical trials, collaboration agreement, milestone payment, PN-881, IL-17 antagonist, Takeda, JNJ, revenue, net income